Celonic

Samanta Cimitan to Become CCO of Lonza

Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President, and a member of the Extended Executive Committee, effective January 1, 2027.

CureVac Cancels two Vaccine Manufacture Deals

German biotech CureVac has canceled manufacturing contracts with two prospective partners for its Covid-19 vaccine CVnCoV while retaining others. The company said on Sept. 14 it would end the arrangements with Germany’s Wacker Chemie and Switzerland’s Celonic Group, but leave the deals with Rentschler Biopharma and Novartis intact.

Celonic: Soenke Brunswieck appointed as Vice President Cell & Gene Therapy

Celonic Acquires Glycotope Bio-manufacturing Facility